GB0919199D0 - Cyloakane(B)azaindole antagonists of prostaglandin D2 recptors - Google Patents

Cyloakane(B)azaindole antagonists of prostaglandin D2 recptors

Info

Publication number
GB0919199D0
GB0919199D0 GBGB0919199.0A GB0919199A GB0919199D0 GB 0919199 D0 GB0919199 D0 GB 0919199D0 GB 0919199 A GB0919199 A GB 0919199A GB 0919199 D0 GB0919199 D0 GB 0919199D0
Authority
GB
United Kingdom
Prior art keywords
cyloakane
recptors
prostaglandin
azaindole
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GBGB0919199.0A
Other versions
GB2465062B (en
GB2465062A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amira Pharmaceuticals Inc
Original Assignee
Amira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amira Pharmaceuticals Inc filed Critical Amira Pharmaceuticals Inc
Publication of GB0919199D0 publication Critical patent/GB0919199D0/en
Publication of GB2465062A publication Critical patent/GB2465062A/en
Application granted granted Critical
Publication of GB2465062B publication Critical patent/GB2465062B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB0919199A 2008-11-06 2009-11-03 Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors Expired - Fee Related GB2465062B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11204408P 2008-11-06 2008-11-06

Publications (3)

Publication Number Publication Date
GB0919199D0 true GB0919199D0 (en) 2009-12-16
GB2465062A GB2465062A (en) 2010-05-12
GB2465062B GB2465062B (en) 2011-04-13

Family

ID=42132183

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0919199A Expired - Fee Related GB2465062B (en) 2008-11-06 2009-11-03 Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors

Country Status (6)

Country Link
US (2) US8034826B2 (en)
AR (1) AR074089A1 (en)
GB (1) GB2465062B (en)
TW (1) TW201022265A (en)
UY (1) UY32225A (en)
WO (2) WO2010054113A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100298368A1 (en) * 2007-11-06 2010-11-25 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
WO2009061676A2 (en) * 2007-11-06 2009-05-14 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
WO2009099901A1 (en) * 2008-02-01 2009-08-13 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
BRPI0907364A2 (en) 2008-02-01 2015-07-14 Amira Pharmaceuticals Inc N, n-disubstituted aminoalkylbiphenyl prostaglandin d2 receptor antagonists
WO2009102893A2 (en) * 2008-02-14 2009-08-20 Amira Pharmaceuticals, Inc. CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
JP2011513242A (en) * 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ，インク． Prostaglandin D2 receptor antagonist
US8426449B2 (en) * 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
US20110112134A1 (en) * 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
WO2010008864A2 (en) 2008-06-24 2010-01-21 Amira Pharmaceuticals, Inc. Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
US20100173313A1 (en) * 2009-01-08 2010-07-08 Amira Pharmaceuticals, Inc. Biomarkers of inflammation
EP2461809A4 (en) 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
US8815917B2 (en) * 2009-08-05 2014-08-26 Panmira Pharmaceuticals, Llc DP2 antagonist and uses thereof
AR080703A1 (en) 2010-03-22 2012-05-02 Actelion Pharmaceuticals Ltd DERIVATIVES OF 3- (HETEROARIL-AMINO) -1,2,3,4-TETRAHIDRO-9H-CARBAZOL, MODULATORS OF PROSTAGLANDINE D2 RECEPTORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USE OF THEM IN THE TREATMENT OF ALLERGIC OR IMMUNE DISORDERS AS ASTHMA.
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
DK2697223T3 (en) 2011-04-14 2016-09-05 Actelion Pharmaceuticals Ltd 7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor
ES2690782T3 (en) 2012-10-24 2018-11-22 Nyu Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm birth
PE20161177A1 (en) * 2014-03-17 2016-11-18 Actelion Pharmaceuticals Ltd DERIVATIVES OF AZAINDOL ACETIC ACID AND THEIR USE AS MODULATORS OF THE PROSTAGLANDIN D2 RECEPTOR
WO2015140701A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
KR20180053345A (en) * 2015-09-15 2018-05-21 이도르시아 파마슈티컬스 리미티드 Crystalline form
CA3075688A1 (en) 2017-09-13 2019-03-21 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
WO2019166635A1 (en) 2018-03-01 2019-09-06 Universität Basel Vizerektorat Forschung Dielectric elastomer transducer and corresponding fabrication process
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor
CN111166899A (en) * 2020-01-07 2020-05-19 安徽省双科药业有限公司 Moist heat sterilization method for sorbitol eye drops
WO2022046605A1 (en) * 2020-08-25 2022-03-03 City Of Hope Compositions and methods for g-protein-coupled receptor 44 detection
CN115466776B (en) * 2022-09-26 2025-06-27 中国医学科学院基础医学研究所 Reagents for detecting eosinophils, applications of eosinophils and their cytoplasmic contents and hydroxydocosahexaenoic acid

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4027278A1 (en) * 1990-08-29 1992-03-05 Bayer Ag HETEROCYCLICALLY SUBSTITUTED INDOLSULFONAMIDE
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
JP2002076352A (en) * 2000-08-31 2002-03-15 Semiconductor Energy Lab Co Ltd Display device and manufacturing method thereof
EP1383771A1 (en) 2001-04-20 2004-01-28 Vertex Pharmaceuticals Incorporated 9-deazaguanine derivatives as inhibitors of gsk-3
AU2002302248B2 (en) * 2001-05-23 2008-03-06 Merck Frosst Canada Ltd. Dihydropyrrolo[1,2-A]indole and tetrahydropyrido[1,2-A]-indole derivatives as prostaglandin D2 receptor antagonists
AR038136A1 (en) 2002-01-24 2004-12-29 Merck Frosst Canada Inc CYCLALCANINDOLS WITH REPLACEMENT WITH FLUOR COMPOSITIONS CONTAINING THESE COMPOUNDS AND TREATMENT METHODS
AU2003231509A1 (en) * 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
MXPA05003660A (en) 2002-10-21 2005-06-08 Warner Lambert Co Tetrahydroquinoline derivatives as crth2 antagonists.
WO2004039807A1 (en) * 2002-10-30 2004-05-13 Merck Frosst Canada & Co. Pyridopyrrolizine and pyridoindolizine derivatives
JP2004182657A (en) 2002-12-04 2004-07-02 Eisai Co Ltd Agent for promoting elevation of hdl level
PL377314A1 (en) 2002-12-20 2006-01-23 Amgen Inc. Asthma and allergic inflammation modulators
PT1471057E (en) 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc UTEIS PYRIMIDYLINYL ACID DERIVATIVES FOR THE TREATMENT OF CRTH2 MEDIATED DISEASES
US20070232681A1 (en) 2003-10-14 2007-10-04 Oxagen Limited Compounds Having Crth2 Antagonist Activity
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
US7714132B2 (en) 2004-03-11 2010-05-11 Actelion Pharmaceuticals, Ltd. Tetrahydropyridoindole derivatives
US20070299122A1 (en) * 2004-11-08 2007-12-27 Tobert Jonathan A Method of Treating Pathological Blushing
CA2594280C (en) * 2004-12-27 2013-04-23 Anja Fecher 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
US7696222B2 (en) 2005-08-12 2010-04-13 Merck Frosst Canada Ltd Indole derivatives as CRTH2 receptor antagonists
EP2407459A1 (en) 2005-09-27 2012-01-18 Shionogi & Co., Ltd. Synthetic intermediate in the production of a sulfonamide derivative having PGD2 receptor antagonistic activity
US7960544B2 (en) * 2005-12-16 2011-06-14 Ironwood Pharmaceuticals, Inc. Useful indole compounds
GB0605743D0 (en) 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
GB0611695D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
ATE530523T1 (en) * 2006-08-07 2011-11-15 Actelion Pharmaceuticals Ltd (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES
SG176477A1 (en) * 2006-08-07 2011-12-29 Ironwood Pharmaceuticals Inc Indole compounds
US7960567B2 (en) 2007-05-02 2011-06-14 Amgen Inc. Compounds and methods useful for treating asthma and allergic inflammation
US8507005B2 (en) 2007-06-21 2013-08-13 Actimis Pharmaceuticals, Inc. Particulates of a CRTH2 antagonist
UA100983C2 (en) 2007-07-05 2013-02-25 Астразенека Аб Biphenyloxypropanoic acid as crth2 modulator and intermediates
GB0719521D0 (en) 2007-10-05 2007-11-14 Argenta Discovery Ltd Compounds
RU2451019C2 (en) * 2007-10-10 2012-05-20 КЕМИТЕК, ЭлЭлСи Heterocyclic compounds as crth2 receptor antagonists
GB0722216D0 (en) 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
GB0722203D0 (en) 2007-11-13 2007-12-19 Oxagen Ltd Use of CRTH2 antagonist compounds
CA2712017C (en) * 2008-01-18 2016-08-09 Oxagen Limited Compounds having crth2 antagonist activity
US20110112134A1 (en) 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
WO2010008864A2 (en) 2008-06-24 2010-01-21 Amira Pharmaceuticals, Inc. Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US20120004233A1 (en) 2009-01-26 2012-01-05 Amira Pharmaceuticals, Inc Tricyclic compounds as antagonists of prostaglandin d2 receptors
EP2461809A4 (en) 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
KR20120046762A (en) 2009-07-31 2012-05-10 판미라 파마슈티칼스, 엘엘씨 Dermal formulations of dp2 receptor antagonists

Also Published As

Publication number Publication date
US20100113503A1 (en) 2010-05-06
GB2465062B (en) 2011-04-13
WO2010054114A3 (en) 2010-08-19
AR074089A1 (en) 2010-12-22
TW201022265A (en) 2010-06-16
US20110301168A1 (en) 2011-12-08
US8034826B2 (en) 2011-10-11
WO2010054114A2 (en) 2010-05-14
WO2010054113A2 (en) 2010-05-14
WO2010054113A3 (en) 2010-08-19
UY32225A (en) 2010-06-30
GB2465062A (en) 2010-05-12

Similar Documents

Publication Publication Date Title
GB0919199D0 (en) Cyloakane(B)azaindole antagonists of prostaglandin D2 recptors
GB2461629B (en) Antagonists of prostaglandin D2 receptors
EP2245022A4 (en) Antagonists of prostaglandin d2 receptors
GB2463788B (en) Heteroaryl antagonists of prostaglandin D2 receptors
EP2310392A4 (en) Tricyclic antagonists of prostaglandin d2 receptors
IL219916A0 (en) Imidazopyridine derivatives as jak inhibitor
IL221823A (en) Piperidin-4-yl-azetidine derivatives as jak1 inhibitors
AP3628A (en) A novel formulation of indomethacin
EP2427054A4 (en) Solid formulations of prostacyclin analogs
EP2576552A4 (en) Benzoquinolone inhibitors of vmat2
IL223300A0 (en) Pyrazole compounds as sigma receptor inhibitors
IL208136A0 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
IL218795A0 (en) Diazepam derivatives as modulators of chemokine receptors
SI2407155T1 (en) Formulations of inecalcitol
EP2444401A4 (en) Novel imidazopyridine compound
TWM402143U (en) Connection sleeve for spray gun
TWM387930U (en) Structure of nozzle
IL243319A0 (en) Intermediates of heteroarylpiperidine and-piperazine derivatives
GB2500540B (en) Riser coupling
AU2009901770A0 (en) Method of constructing floors
IL244032B (en) Intermediates for the preparation of pyrazolyl quinoxaline kinase inhibitors
TWM401708U (en) Structure of quick-release
PL392084A1 (en) Adhesive spraying head
GB0803895D0 (en) Inhibitors of glyoxalase
PH32010000832S1 (en) Toilet block applicator

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20111117 AND 20111123

PCNP Patent ceased through non-payment of renewal fee

Effective date: 20131103